Reverse Aging: The Real Science Behind It In 2026

In September 2015, a 44-year-old biotech CEO flew to Colombia and let doctors inject her with two experimental gene therapies that had never been tested in a human being.

She did this to herself. On purpose. Without FDA approval, because the FDA would never have approved it.

Her name was Elizabeth Parrish. Six months later, blood tests appeared to show that her telomeres, the protective caps on the ends of her chromosomes, had lengthened by the equivalent of 20 years. She called herself patient zero in the fight against aging itself.

Reverse aging is the idea that the biological processes responsible for getting older are not fixed and irreversible, but can, at least partially, be slowed, stopped, or run backward. It is no longer a fringe idea confined to longevity podcasts. It is now a serious, well-funded, and increasingly well-evidenced area of biomedical research, pursued by Harvard professors, FDA-cleared clinical trials, and billion-dollar laboratories.

This article covers where that research actually stands. The real studies. The real institutions. The real controversy. And the story of the woman who decided not to wait for any of it.

The stakes behind this research extend well beyond vanity. Aging is the single largest shared risk factor behind heart disease, cancer, dementia, and diabetes combined, and age-related disease accounts for trillions of dollars in annual healthcare spending in the United States alone. If even a handful of the interventions below prove out in large human trials, the effect on global healthspan, and on the economics of healthcare itself, would dwarf the impact of curing any single disease in isolation. That is the scale of ambition driving the laboratories, billionaires, and self-experimenters in this story.

Table of Contents

Who Is Elizabeth Parrish, and What Did She Actually Do?

Elizabeth Parrish founded a small biotech company called BioViva, based on Bainbridge Island near Seattle. The company’s stated mission was to treat aging itself as a disease, rather than as the unavoidable backdrop to disease.

In September 2015, Parrish received two of her own company’s experimental therapies. The first was a myostatin inhibitor, intended to protect against age-related muscle loss. The second was a telomerase gene therapy, intended to lengthen telomeres and counteract the cellular aging associated with their shortening.

The procedure was done outside the United States specifically to avoid the regulatory process that would otherwise have been required. This drew sharp criticism from much of the biotech community, who argued that self-experimentation outside any clinical trial framework was reckless and scientifically meaningless, no matter how it turned out.

Six months later, BioViva reported that blood samples taken by an independent testing laboratory showed Parrish’s telomeres had lengthened from 6.71 kilobases to 7.33 kilobases. According to the company, this implied her white blood cells had become biologically younger by roughly 20 years.

The results were never published in a peer-reviewed scientific journal. They came from a single person, with no control group, no blinding, and no independent replication. Critics, including many longevity researchers who otherwise supported the broader goal of treating aging, pointed out that one telomere measurement before and after a treatment proves very little on its own.

What it did prove, whether or not the biology held up to scrutiny, was that someone was willing to bet her own body on the idea that aging could be reversed. According to a ten-year retrospective published in 2026, BioViva has since expanded its work well beyond telomerase, now targeting a broader set of genes including klotho, follistatin, FGF21, and partial reprogramming factors. Parrish did not deliver a cure. She did force a speculative idea into public conversation, and kept that conversation alive for a decade.

Bryan Johnson: A Decade Later, a Different Kind of Self-Experiment

Parrish was not the last person to turn her own body into a research project. A decade later, tech entrepreneur Bryan Johnson took a far more systematic, far more expensive version of the same idea and turned it into a media phenomenon.

Johnson, who sold his payment company Braintree to PayPal for 800 million dollars in 2013, launched Project Blueprint in 2021. Rather than a single gene therapy, Blueprint is an enormous, continuously adjusted stack of diet, exercise, sleep, supplements, and medical monitoring, costing him roughly two million dollars a year and overseen by a team of more than 30 physicians.

Johnson reports a biological age, measured through epigenetic clocks including DunedinPACE and GrimAge, that runs several years behind his calendar age, with some organ-specific measurements showing even larger gaps. He publishes his blood panels and protocols openly, which has made him both the most transparent and the most scrutinised figure in this entire field.

The scrutiny has been warranted in places. Johnson discontinued growth hormone therapy after it raised his intracranial pressure and blood glucose. He removed rapamycin from his stack in 2026 after side effects. A widely covered plasma exchange experiment, in which his teenage son donated plasma to him, showed no measurable benefit for Johnson himself, while plasma donated from Johnson to his 70-year-old father did appear to slow his father’s aging markers, an asymmetry that intrigued researchers more than the original headline did.

Independent critics, including the longevity supplement company NOVOS, have pointed out that other individuals using far cheaper, far less extreme protocols have posted larger biological age reductions on the same epigenetic tests. Oliver Zolman, a physician who formerly led Johnson’s medical team, has since argued publicly that the field’s credibility depends on separating genuine clinical evidence from what he calls “bad medical advice being given by social media influencers.”

Taken together, Parrish and Johnson represent two very different bets on the same idea, one through a single irreversible act in 2015, the other through an open-ended, constantly revised experiment running for years in public view. Neither has produced peer-reviewed proof that their personal results generalise to anyone else. Both have undeniably pulled enormous public attention toward a field that, until recently, mostly lived in academic journals nobody outside it read.

What Does “Reversing Aging” Actually Mean?

Before going further, it helps to be precise about what scientists mean when they say aging can be reversed, because the phrase gets used loosely.

Your chronological age is simply how many years you have been alive. Nobody is claiming to reverse that. What researchers are targeting is biological age: a measure of how old your cells, tissues, and organs actually appear at the molecular level, based on markers like DNA methylation patterns, telomere length, and the accumulation of senescent cells.

Two people can share the same chronological age and have meaningfully different biological ages. This is precisely the territory explored in our coverage of centenarian genetics, where some individuals appear to age far more slowly than the calendar would suggest.

The tools used to measure biological age, most notably the Horvath epigenetic clock, are what make reverse aging research testable at all. Without a way to measure biological age independently of birth certificates, claims of “reversal” would be unfalsifiable. With it, researchers can show, in controlled studies, that a given intervention measurably moves the needle backward.

The Twelve Hallmarks of Aging: The Map Behind Every Method in This Article

Every intervention covered in this article is, whether its developers say so explicitly or not, aimed at one or more items on a specific scientific checklist.

In 2013, a team led by Spanish biochemist Carlos López-Otín published a paper in the journal Cell proposing nine hallmarks of aging, common cellular and molecular processes that drive aging across essentially all studied organisms. In 2023, the same team, now including Maria Blasco, Linda Partridge, Manuel Serrano, and Guido Kroemer, expanded the list to twelve in an updated Cell paper titled “Hallmarks of Aging: An Expanding Universe.”

The twelve hallmarks include genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, disabled macroautophagy, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, chronic inflammation, and dysbiosis, an imbalance in the body’s microbial communities.

This framework is not just an academic curiosity. It is the shared language that lets researchers compare wildly different interventions on equal footing. Partial reprogramming primarily targets epigenetic alterations. HBOT and senolytics primarily target telomere attrition and cellular senescence. Fasting primarily targets deregulated nutrient sensing and disabled macroautophagy. Plasma dilution primarily targets altered intercellular communication and chronic inflammation.

According to the 2023 update, no single hallmark acts alone. They reinforce each other, which is precisely why researchers increasingly favour combination approaches over any single silver-bullet intervention, and why the field has shifted its language from curing aging to intercepting it across multiple fronts simultaneously.

Klotho: The Aging-Suppressor Gene Named After a Greek Fate

Among the genes BioViva now lists as a current target, one has a backstory unusual enough to be worth telling on its own.

Klotho is named after one of the three Fates in Greek mythology, the one who spins the thread of life. The gene was discovered in 1997 when Japanese researchers noticed that mice with a defective version aged at an accelerated, almost cartoonish rate, developing osteoporosis, arteriosclerosis, and cognitive decline within months rather than years.

The reverse experiment proved just as striking. Mice genetically engineered to overexpress Klotho lived substantially longer than normal mice, with improved cognitive function well into old age.

According to a 2023 study published in Nature Aging, researchers found that the longevity factor Klotho enhances cognition even in aged nonhuman primates, a result that matters considerably more than another mouse study, since primate biology sits much closer to human biology.

A comprehensive 2025 review in the International Journal of Nanomedicine found that Klotho counters the majority of the twelve hallmarks of aging directly. It improves mitochondrial function, reduces oxidative stress, slows telomere attrition, and suppresses the same chronic inflammatory signalling pathways implicated in atherosclerosis, diabetes, and Alzheimer’s disease.

Klotho levels decline naturally and measurably with human age, which has made restoring them, through gene therapy, recombinant protein injection, or small molecules that boost the body’s own production, one of the more mechanistically well-justified targets in the entire reverse aging field, even though no human Klotho-based therapy has yet reached late-stage clinical trials.

Epigenetic Clocks: How Scientists Actually Measure a “Younger” Result

Every claim of reversed biological age in this article rests on a specific measurement tool, and understanding what these tools do and do not capture is essential to reading the evidence correctly.

The original epigenetic clock, developed by biostatistician Steve Horvath in 2013, estimates biological age by examining DNA methylation patterns at several hundred specific sites across the genome. Methylation, a chemical tag attached to DNA that influences gene activity, changes in remarkably predictable ways as cells age, closely enough that Horvath’s clock can estimate a person’s age from a tissue sample to within a few years of accuracy.

Later clocks refined this idea for different purposes. GrimAge, developed by Horvath’s own team, was trained specifically to predict mortality risk and time to death, making it more clinically predictive than the original clock. PhenoAge incorporates blood biomarkers alongside methylation data. DunedinPACE, used by Bryan Johnson and built from New Zealand’s long-running Dunedin cohort study, measures the pace of aging directly, expressed as biological years accumulated per calendar year, rather than a single age snapshot.

These tools are genuinely powerful research instruments, validated against real health outcomes across large populations. They are not, however, infallible rulers. Different clocks can disagree with each other on the same blood sample, and a clock trained on one population does not always generalise perfectly to another.

This matters enormously when reading personal anecdotes about reversed biological age, including Bryan Johnson’s own published numbers. A favourable reading on one clock is informative. It is not the same as proof that a person’s actual risk of disease or death has dropped by an equivalent margin.

How to Evaluate Reverse Aging Claims You Encounter Online

Given how much money, ego, and genuine hope rides on this field, it is worth equipping you with the same questions researchers use to separate signal from noise.

First, ask whether the claim comes from a single self-reported case or from a controlled trial with a comparison group. Elizabeth Parrish’s telomere result and Bryan Johnson’s biological age scores are both single-subject data points. They are interesting. They are not evidence that the same protocol would work the same way in you.

Second, check whether the researchers or company behind a study have a direct financial stake in its outcome, as is the case with the Tel Aviv University HBOT trial and several commercial epigenetic clock providers. A conflict of interest does not automatically mean a result is wrong, but it does mean independent replication matters more than usual before treating the finding as settled.

Third, distinguish between animal results and human results. Rapamycin’s lifespan extension in mice is one of the most reproduced findings in aging biology. Whether it extends healthy lifespan in humans without an underlying disease remains, as of 2026, genuinely unproven.

Fourth, be aware that even celebrated researchers attract serious scientific pushback. David Sinclair’s bestselling book Lifespan has been praised by some researchers as visionary and criticised by others, including biochemist Charles Brenner and University of Alabama biology professor Steven Austad, for what they describe as excessive claims and counterfactual statements about longevity genes. This kind of open disagreement among credentialed scientists is not a reason to dismiss the field. It is a sign the field is functioning as science should, with claims facing real scrutiny rather than uncritical acceptance.

Partial Cellular Reprogramming: The Most Scientifically Credible Frontier

If there is one approach that the scientific establishment takes most seriously, it is partial cellular reprogramming, built on a Nobel Prize-winning discovery from 2006.

That year, Shinya Yamanaka showed that introducing four specific proteins into an adult cell could reset it all the way back to an embryonic, pluripotent state. These four proteins, OCT4, SOX2, KLF4, and c-MYC, are collectively known as the Yamanaka factors, or OSKM.

Full reprogramming erases a cell’s identity entirely. A skin cell stops being a skin cell. This is useful for stem cell research, but useless and dangerous for treating a living, aging body, since fully reprogrammed cells can form tumours.

The breakthrough came when researchers, including David Sinclair’s laboratory at Harvard, discovered that briefly and partially activating just three of the four factors, leaving out the more tumour-associated c-MYC, could restore youthful function to old cells without erasing what kind of cell they were.

In a landmark 2020 study that made the cover of Nature, Sinclair’s team used this three-factor approach, OSK, to restore vision in mice with damaged optic nerves, reversing a form of vision loss that mimics glaucoma. The cells became biologically younger by epigenetic measures, without losing their identity as retinal neurons.

By 2023, a related team at Rejuvenate Bio extended this further, using gene therapy to deliver OSK systemically in naturally aged mice rather than mice with an artificial accelerated-aging disease. The treated mice lived 109 percent longer on average than untreated controls, and showed improved frailty scores, meaning they were not just living longer but living better.

This is where the story moves from mice to people. In January 2026, the FDA cleared Sinclair’s company, Life Biosciences, to begin the first human clinical trial of partial epigenetic reprogramming, targeting patients with glaucoma and a rare condition called NAION that damages the optic nerve.

“Nobody in the world believed that it would work until we tried it,” Sinclair said, referring to the initial scepticism that three factors, rather than the full four that won Yamanaka his Nobel Prize, could safely produce a meaningful effect.

The trial is explicitly focused on safety first. Restoring lost vision would be a secondary, hoped-for outcome. Researchers from Altos Labs, a longevity company with deep ties to the same scientific community, have separately published mechanistic work describing a pattern they call “mesenchymal shift,” in which aging cells lose their specialised identity and regress toward a less efficient, more primitive state, a pattern partial reprogramming appears to directly counteract.

This is also, notably, an extremely well-funded race. Altos Labs, Retro Biosciences, and NewLimit, backed respectively by Yuri Milner, Sam Altman, and Brian Armstrong, are all competing to bring some version of partial reprogramming into the clinic.

Hyperbaric Oxygen Therapy: Lengthening Telomeres With Pressurised Air

Long before gene therapy entered the picture, researchers in Israel found something unexpected while studying a far simpler intervention: pressurised oxygen.

Hyperbaric oxygen therapy, or HBOT, involves breathing concentrated oxygen inside a pressurised chamber. It has been used for decades to treat decompression sickness and wound healing. What researchers at Tel Aviv University and Shamir Medical Center wanted to know was whether it could do anything for aging itself.

In a 2020 clinical trial led by Professor Shai Efrati, 35 healthy adults aged 64 and older underwent 60 hyperbaric sessions over 90 days, with no other lifestyle, diet, or medication changes. Blood was drawn before, during, and after the protocol.

The results, published in the peer-reviewed journal Aging, showed telomere lengthening of up to 38 percent in the immune cells studied. The same protocol reduced the proportion of senescent cells, the worn-out, zombie-like cells discussed in our coverage of telomeres and cellular aging, by up to 37 percent.

“Today telomere shortening is considered the Holy Grail of the biology of aging,” Efrati said, describing the result as proof that aging could be targeted and reversed at the basic cellular level using a tool far simpler than gene therapy.

One important caveat deserves mentioning directly, in the interest of giving you the full picture rather than just the headline. Efrati is a shareholder in Aviv Scientific, the company that commercialises this HBOT protocol, and other co-authors work for the same company. This is disclosed in the paper itself, and it does not invalidate the data, but it is the kind of financial interest that responsible science journalism should always name.

Independent replication by laboratories with no commercial stake in HBOT clinics would meaningfully strengthen confidence in these findings. As of 2026, that broader independent confirmation is still an active area of ongoing research rather than a settled matter.

Fasting and Caloric Restriction: The Oldest Known Longevity Lever

Of every intervention discussed in this article, caloric restriction has the longest and most consistent evidence behind it, stretching back nearly a century of animal research.

The modern human-relevant version of this idea is largely the work of Valter Longo, director of the Longevity Institute at the University of Southern California. Longo studied under calorie-restriction pioneer Roy Walford at UCLA before developing what he calls the fasting-mimicking diet, or FMD.

The FMD is a five-day, low-calorie, low-protein, plant-based eating pattern designed to trick the body into a fasting state without requiring true water-only fasting. According to Longo, this triggers cellular cleanup processes, particularly autophagy, in which cells break down and recycle damaged internal components.

Longo’s laboratory has published randomized clinical trials showing that cycling through the FMD periodically, roughly once every one to three months, reduces multiple risk factors associated with aging, diabetes, cancer, and cardiovascular disease. A 2025 randomized cross-over trial published in Cell Reports Medicine found measurable chemosensory and cardiometabolic improvements following the protocol.

“People become two and a half years younger,” Longo said in 2025, describing biological age changes observed in trial participants, though he is careful to frame this as a reduction in disease risk factors rather than literal time travel.

The cellular mechanism behind this effect runs through a small set of nutrient-sensing pathways that appear repeatedly throughout this article. When calories are scarce, a cellular energy sensor called AMPK activates, while a growth-promoting pathway called mTOR, the same target rapamycin inhibits directly, winds down. This shift flips cells from a growth-and-build mode into a maintenance-and-repair mode, switching on autophagy, the process by which cells break down and recycle their own damaged components, including misfolded proteins and worn-out mitochondria.

A family of proteins called sirtuins, which require a coenzyme called NAD+ to function, also become more active during fasting, helping to coordinate this metabolic switch and explaining why NAD+ precursor supplements are so often discussed in the same breath as fasting protocols. Nutrient scarcity, in effect, hands a cell’s internal cleanup crew the resources and the signal it needs to do a more thorough job.

This is also precisely why metformin and rapamycin are described as caloric restriction mimetics. They engage the same AMPK and mTOR machinery pharmacologically, attempting to capture some of fasting’s cellular benefits without requiring anyone to actually go five days eating 800 calories.

Separately, the CALERIE trial, a major human caloric restriction study, found that sustained moderate calorie reduction improved cardiometabolic risk factors and slowed certain biological aging markers, lending independent support to the broader principle even outside Longo’s specific protocol.

Longo himself is on record wanting to live to a healthy 120 or 130. Whether or not he gets there, the fasting research he has built is, by a wide margin, the most rigorously human-tested intervention in this entire field.

Young Blood, Diluted Blood, and an Accidental Discovery

The idea that young blood might rejuvenate old bodies has a strange and important history, one that mostly disproved itself on the way to a more useful discovery.

In 2005, researchers Irina and Michael Conboy at UC Berkeley surgically joined the circulatory systems of an old mouse and a young mouse, a technique called parabiosis. The old mouse showed genuine signs of rejuvenation.

This launched a wave of excitement, and a wave of companies, around the idea that specific youthful proteins in young blood were the active ingredient. Some companies began offering young plasma infusions directly to paying customers.

Then the Conboy lab ran a more careful follow-up. When they exchanged blood between young and old mice without physically joining the animals, the young mice got measurably worse, not better. Young blood circulating through old veins, on its own, did not rejuvenate anything.

This led to a different hypothesis entirely: that aging is driven less by a deficiency of youthful factors, and more by an accumulation of harmful ones. To test this, the Conboys simply diluted old plasma, replacing part of it with plain saline and albumin, a basic blood protein, without adding any young blood at all.

The diluted old mice showed rejuvenation across muscle, liver, and brain tissue, including increased birth of new neurons and reduced inflammation, published in the journal Aging in 2020. Dilution alone, with no young blood whatsoever, outperformed the original parabiosis result.

By 2022, the same approach was tested directly in humans through therapeutic plasma exchange, a long-established medical procedure normally used for autoimmune conditions. A study published in GeroScience found that repeated plasma exchange sessions shifted ten distinct protein biomarkers toward a younger systemic profile.

A 2025 follow-up clinical trial from the Buck Institute, published in Aging Cell, found that plasma exchange lowered participants’ biological age by an average of 1.32 years, with some protocols showing reductions of up to 2.6 years. The procedure’s safety record across 240 sessions showed only one mild allergic reaction.

Repurposed Drugs: Metformin, Rapamycin, and the Hallmarks of Aging

Some of the most discussed reverse aging candidates were not designed for aging at all. They were designed for diabetes and organ transplants, and researchers noticed their side effects looked suspiciously like slower aging.

Metformin has been prescribed for type 2 diabetes since the 1950s. Large observational studies have repeatedly found that diabetic patients taking metformin sometimes live longer than non-diabetic people who take nothing, an effect that should not be possible if metformin were doing nothing beyond normal glucose control.

This observation led to the TAME trial, Targeting Aging with Metformin, a large multicentre study designed specifically to test whether metformin can delay the onset of multiple age-related diseases simultaneously in non-diabetic older adults, rather than just treating one disease at a time.

Rapamycin, originally developed as an immunosuppressant for organ transplant patients, works through a different but related pathway, inhibiting a cellular growth regulator called mTOR. In mice, rapamycin reliably extends lifespan by 9 to 14 percent when started in middle age, one of the most consistently reproduced findings in all of aging biology.

Both drugs are thought to work partly by mimicking the cellular effects of caloric restriction, activating the same nutrient-sensing pathways that fasting triggers, without requiring anyone to actually stop eating.

The honest caveat here matters as much as the promise. As of 2026, no completed human trial has proven that either drug extends healthy lifespan in people without an underlying metabolic condition. The case for diabetics and organ transplant patients is much stronger than the case for using these drugs preventively in otherwise healthy adults.

Why the FDA Does Not Recognise “Aging” as a Disease, and Why That Matters

There is a regulatory obstacle sitting underneath every claim in this article that rarely makes the headlines, but shapes the entire field’s strategy.

The U.S. Food and Drug Administration does not currently recognise aging itself as a disease or condition that a drug can be approved to treat. This is precisely why the TAME trial measures metformin’s effect on delaying multiple specific diseases of aging, rather than aging as a single outcome, and why Life Biosciences’ partial reprogramming trial is officially framed around treating glaucoma and NAION, not reversing aging broadly.

Researchers and advocacy organisations, including the American Federation for Aging Research, have spent years lobbying regulators to accept “delayed onset of multiple age-related conditions” as a legitimate trial endpoint, precisely because no existing pathway lets a company seek approval for an anti-aging drug as such.

This regulatory gap explains an otherwise puzzling pattern: nearly every legitimate reverse aging therapy currently in human trials is technically being tested against a single named disease, optic nerve damage, type 2 diabetes risk, or organ transplant rejection, even when the scientists running the trial are explicitly motivated by aging biology more broadly. Until that changes, the clinical proof of any reverse aging method will keep arriving sideways, through diseases, rather than head-on.

Other Approaches Being Explored Right Now

Several additional strategies are active areas of research, each targeting a different one of the recognised hallmarks of biological aging.

Senolytic drugs, which selectively clear out senescent cells rather than diluting or reprogramming them, are covered in detail in our dedicated article on senolytics and are currently in trials alongside several of the interventions named above.

NAD+ precursor supplements, including NMN and NR, aim to restore levels of a coenzyme essential for cellular energy production and DNA repair that decline measurably with age. Human trial results so far show no major safety concerns, but evidence for meaningful biological age reversal in healthy people remains limited and mixed.

Stem cell therapies aim to replenish the body’s pool of regenerative cells directly, rather than rejuvenating existing ones in place. This approach faces significant manufacturing and safety hurdles, including the same tumour risk concerns that shaped the design of partial reprogramming research.

Why “Reversing” Aging Is Different From Simply Slowing It

It is worth being precise about a distinction that often gets blurred in headlines, because it changes what each intervention discussed here is actually claiming to do.

Slowing aging means reducing the rate at which biological damage accumulates going forward. Reversing aging means actively undoing damage that has already accumulated, moving a measured biomarker backward rather than simply flattening its future trajectory.

Caloric restriction and rapamycin are best understood, on current evidence, as primarily slowing interventions. Partial reprogramming, HBOT’s telomere effects, and plasma dilution are the candidates with the strongest direct evidence of genuine reversal on specific biomarkers, which is precisely why they generate the most excitement and the most scrutiny simultaneously.

None of this happens in isolation from the underlying genetics. The epigenetic machinery that partial reprogramming targets is the same machinery explored in our article on epigenetics and gene expression. The senescent cells that HBOT and senolytics both target are the same cells discussed in our coverage of telomeres and cellular aging. Reverse aging research is not a separate field from genetics. It is genetics, applied with a specific, audacious goal in mind.

What Scientists Say

David Sinclair has described his work through what he calls the information theory of aging, the idea that aging is fundamentally a loss of epigenetic information rather than damage to the DNA sequence itself, and that this lost information can, in principle, be restored.

Shai Efrati has called telomere shortening “the Holy Grail of the biology of aging,” and argues that his HBOT data provide a foundation for understanding that the aging process can be targeted, not merely managed.

Irina Conboy’s plasma dilution work led her to a conclusion that runs against decades of young-blood mythology: it is not what young blood adds that matters, she argues, but what old blood accumulates, and removing that accumulation may be the more tractable target.

Valter Longo has spent over three decades arguing that the most powerful longevity lever available to humans right now does not require a laboratory at all, simply a well-timed, well-designed pattern of eating.

Carlos López-Otín, whose framework now organises how the entire field thinks about aging, has emphasised that the twelve hallmarks “are highly interconnected,” meaning that interventions targeting one process frequently produce measurable benefits in several others simultaneously. This interconnectedness is precisely why researchers increasingly favour combination protocols, pairing a senolytic with exercise, or fasting with a partial reprogramming therapy, over the search for one intervention that does everything.

Frequently Asked Questions

Has anyone actually reversed aging in a human being?

Several human studies have shown reversal of specific biological aging markers, including telomere lengthening through hyperbaric oxygen therapy and reduced biological age scores through therapeutic plasma exchange. No study has demonstrated full-body reversal of aging or extended human lifespan through any of these methods, since lifespan studies in humans take decades to complete.

Is Elizabeth Parrish’s gene therapy result considered legitimate science?

Parrish’s 2015 self-experiment was never published in a peer-reviewed journal and involved only one person with no control group, so it does not meet the standards of rigorous clinical evidence. It is best understood as a provocative case study that drew public attention to gene therapy approaches that her company and others have since pursued through more rigorous channels.

What is partial cellular reprogramming?

Partial cellular reprogramming uses a subset of the Yamanaka factors, typically OCT4, SOX2, and KLF4, briefly activated in cells to restore youthful gene expression and function without erasing the cell’s specialised identity. It has reversed vision loss and extended lifespan in mice and entered its first FDA-cleared human safety trial in January 2026.

Does fasting actually reverse aging or just slow it down?

Current evidence suggests fasting and caloric restriction primarily slow the accumulation of age-related damage and reduce disease risk factors, rather than reversing existing damage. Some trials have shown reductions in biological age scores following fasting protocols, but the dominant, best-supported effect is protective rather than reparative.

Are rapamycin and metformin safe to take for anti-aging purposes?

Both drugs have established safety profiles for their original approved uses, diabetes for metformin and transplant rejection for rapamycin, but neither has completed a trial proving they extend healthy lifespan in people without those underlying conditions. Medical guidance generally cautions against self-prescribing either drug specifically for anti-aging purposes outside of clinical trial settings.

What are the hallmarks of aging?

The hallmarks of aging are a set of twelve common biological processes identified by researchers, including genomic instability, telomere attrition, epigenetic alterations, cellular senescence, mitochondrial dysfunction, and chronic inflammation, that drive aging across nearly all studied organisms. First proposed in 2013 and expanded in a 2023 paper in the journal Cell, this framework gives researchers a shared way to compare how different reverse aging interventions, from fasting to gene therapy, target different underlying mechanisms.

What is Klotho and why is it significant for aging research?

Klotho is a gene and protein, named after a Greek mythological figure who spins the thread of life, that suppresses multiple hallmarks of aging simultaneously. Mice lacking functional Klotho age at a dramatically accelerated rate, while mice engineered to produce extra Klotho live longer with better cognitive function. A 2023 study found that Klotho improves cognition in aged nonhuman primates, and it is currently one of several genes targeted by BioViva’s ongoing research programme.

What is an epigenetic clock and can it be trusted?

An epigenetic clock is a laboratory tool that estimates biological age by analysing patterns of DNA methylation, a chemical modification to DNA that changes predictably with age. Clocks including Horvath’s original model, GrimAge, PhenoAge, and DunedinPACE are well-validated research tools linked to real health outcomes, but different clocks can produce different results from the same sample, and a favourable score is not the same as proof of reduced disease risk. They are best understood as informative research instruments rather than infallible verdicts on how “old” a person truly is.

Sources

Primary peer-reviewed research:

Institutional and science journalism coverage:

Share on Facebook

Post on X

Save

Discover more from Web News For Us

Subscribe to get the latest posts sent to your email.

Reverse Aging: The Real Science Behind It in 2026